All In Biotech

Drug Trial Radar · NCT03395080

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

111

Actual

Start

Mar 5, 2018

Primary completion

Sep 9, 2020

Study completion Jan 27, 2021

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Conditions

  • Endometrial Cancer
  • Uterine Cancer
  • Ovarian Cancer
  • Carcinosarcoma

Interventions

  • PaclitaxelDrug

    Administered by IV infusion

  • 300mg DKN-01Drug

    Administered by IV infusion

  • 600mg DKN-01Drug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Objective Response Rate (ORR) in EEC or EOC PatientsTime frame: Baseline to study completion (approximately 6 months)
  2. Number of Subjects With Objective Response Rate (ORR) in Carcinosarcoma (MMMT) PatientsTime frame: Baseline to study completion (approximately 6 months)

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • HonorHealth

    Scottsdale, Arizona

  • Florida Cancer Specialists & Research Institute

    West Palm Beach, Florida

  • University of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • HCA Midwest Health System Clinical Research

    Kansas City, Missouri

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center

    Hilliard, Ohio

  • Stephenson Cancer Center - University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • The University of Tennessee West Cancer Center

    Germantown, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • Froedtert and Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.